A non-binding MOU between Aphria and Canadian bio-tech company Rapid Dose Therapeutics will give Aphria exclusive global preferred rights to produce, distribute and sell QuickStrip around the world, the company announced last week.
The company said RDT’s QuickStrip is an easy-to-use, safe and effective drug-delivery system. The fast-dissolving oral strip was developed in conjunction with McMaster University through the Adronov Research Group.
RDT CEO Mark Upsdell said partnering with Aphria is a natural fit for RDT.
“Aphria’s innovation-led approach along with the company’s substantial infrastructure, capacity and global reach make this an ideal strategic partnership for both companies.” he said.
According to RDT’s website:
- QuickStrip rapidly releases an expansive list of pharmaceuticals, emulsified oils, and over-the-counter medicines which enter the blood stream through a rapid dose pathway without being degraded or modified by first pass metabolism in the liver.
- Studies show the QuickStrip technology delivery mimics blood concentrations over time to intravenous injection.
- Sublingual and transmucosal transport of active molecules result from the rapid dissolution of QuickStrip combined with the proprietary technology.
Aphria’s chief commercial officer Jakob Ripshtein said the company is looking forward to extending the partnership to other markets around the world.
“They have developed a truly innovative product that will offer both patients and consumers a new way to consume and experience cannabis,” he said.
Under the proposed definitive agreement, Aphria will have the ability to bring products developed using RDT’s QuickStrip technology to international markets.